Evidence map›Paper›PMID 34052418›Full record

ReviewInfection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases2021

Pathomechanisms, therapeutic targets and potent inhibitors of some beta-coronaviruses from bench-to-bedside.

Yusuf Oloruntoyin Ayipo, Sani Najib Yahaya, Waleed A Alananzeh, Halimah Funmilayo Babamale, Mohd Nizam Mordi

Open access · greenAbstract readReview
In one paragraph

Review in Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Can iron chelators ameliorate viral infections?Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2024
    Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 2 countries.

Yusuf Oloruntoyin AyipoCentre for Drug Research, Universiti Sains Malaysia, USM, 11800 Pulau Pinang, Malaysia; Department of Chemistry, Kwara State University, P. M. B. 1530, Malete, Ilorin, Nigeria.
Sani Najib YahayaCentre for Drug Research, Universiti Sains Malaysia, USM, 11800 Pulau Pinang, Malaysia.
Waleed A AlananzehCentre for Drug Research, Universiti Sains Malaysia, USM, 11800 Pulau Pinang, Malaysia.
Halimah Funmilayo BabamaleSchool of Chemistry, Universiti Sains Malaysia, USM, 11800 Pulau Pinang, Malaysia.
Mohd Nizam MordiCentre for Drug Research, Universiti Sains Malaysia, USM, 11800 Pulau Pinang, Malaysia. Electronic address: mnizam@usm.my.
Universiti Sains Malaysia · MY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since the emergence of their primitive strains, the complexity surrounding their pathogenesis, constant genetic mutation and translation are contributing factors to the scarcity of a successful vaccine for coronaviruses till moment. Although, the recent announcement of vaccine breakthrough for COVID-19 renews the hope, however, there remains a major challenge of accessibility to urgently match the rapid global therapeutic demand for curtailing the pandemic, thereby creating an impetus for further search. The reassessment of results from a stream of experiments is of enormous importance in identifying bona fide lead-like candidates to fulfil this quest. This review comprehensively highlights the common pathomechanisms and pharmacological targets of HCoV-OC43, SARS-CoV-1, MERS-CoV and SARS-CoV-2, and potent therapeutic potentials from basic and clinical experimental investigations. The implicated targets for the prevention and treatment include the viral proteases (M

Indexed as

Host-Pathogen InteractionsAntiviral AgentsCoronavirusCoronavirus InfectionsCoronavirus OC43, HumanHumansMiddle East Respiratory Syndrome CoronavirusRandomized Controlled Trials as TopicSARS-CoV-2Viral ProteinsAntiviral AgentsViral ProteinsBiochemical analysisCoronaviridaeDrug targetsMulti-target pharmacologyPathophysiologyTherapeutic design

Identifiers

PMID34052418
PMCPMC8159710
OpenAlexW3165145394

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.